Nemaura Medical (Nemaura Medical) GF Value : $0.00 (As of May. 01, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Nemaura Medical GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-01), Nemaura Medical's share price is $0.05345. Nemaura Medical's GF Value is $0.00. Therefore, Nemaura Medical's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Nemaura Medical is Not Valued.

Nemaura Medical (OTCPK:NMRD) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Nemaura Medical's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.05345	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nemaura Medical GF Value Related Terms

Thank you for viewing the detailed overview of Nemaura Medical's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Nemaura Medical (Nemaura Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nemaura Medical Inc (OTCPK:NMRD) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

57 West 57th Street, New York, NY, USA, 10019

Website

https://www.nemauramedical.com

Nemaura Medical Inc is a medical technology company developing sugarBEAT as a non-invasive, affordable, and flexible Continuous Glucose Monitor (CGM) designed for people with diabetes and pre-diabetics to manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading. SugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with an app displaying glucose readings at five-minute intervals for periods up to 24 hours.

Executives

Bashir Timol	director, 10 percent owner, officer: Chief Business Officer	C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Chowdhury Dewan Fazlul Hoque	director, 10 percent owner, officer: CEO & President	CHAMWOOD BUILDING, HOLYWELL PARK, ASHBURY ROAD, LOUGHBOROUGH LEICS X0 LE113AQ
Salim Natha	director	LOUGHBOROUGHUNIVERSITYSCIENCE&ENTERPRISE, PARKS, 5 OAKWOOD DRIVE, LOUGHBOROUGH, LEICESTERSHIRE X0 LE113QF
Justin James Mclarney	officer: Chief Financial Officer	C/O NEMAURA MEDICAL INC., 57 WEST 57TH STREET, MANHATTAN NY 10019
Sufyan Ismail	10 percent owner	C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Thomas Peter Moore	director	C/O NEMAURA MEDICAL, INC., 57 WEST 57TH STREET, MANHATTAN NY 10019
Timothy Christopher Johnson	director	C/O NEMAURA MEDICAL INC., 57 WEST 57TH STREET, MANHATTAN NY 10019
Iain Anderson	officer: CFO	LOUGHBOROUGHUNIVERSITYSCIENCE&ENTERPRISE, PARKS, 5 OAKWOOD DRIVE, LOUGHBOROUGH, LEICESTERSHIRE X0 LE113QF
Kathryn Farrar	officer: Director of Finance	C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Julie Pomeroy	officer: Director of Finance	C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Richard Toon	officer: Technical & Bus. Dev. Manager	C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT